Jeff Smith's most recent trade in Precision Biosciences Inc was a trade of 16,667 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 16,667 | 33,333 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 16,667 | 126,851 (0%) | 0% | 0 | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 17 Feb 2026 | 4,925 | 121,926 (0%) | 0% | 3.8 | 18,912 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 16,219 | 16,219 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 16,219 | 120,384 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 10,447 | 104,165 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 10,447 | 10,447 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 20 Jan 2026 | 10,200 | 110,184 (0%) | 0% | 4.0 | 41,106 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 2,500 | 93,718 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 2,500 | 0 | - | - | Restricted Stock Units | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 17,666 | 35,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 17,666 | 36,018 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.67 per share. | 12 Jan 2026 | 9,310 | 26,708 (0%) | 0% | 22.7 | 211,090 | Common Stock |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 20,000 | 28,890 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 20,000 | 20,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 05 Jan 2026 | 10,538 | 18,352 (0%) | 0% | 25.1 | 264,471 | Common Stock |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 411 | 8,082 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 336 | 8,419 | - | - | Common Share Equivalent | |
| Kenvue | Jeffrey C. Smith | Director | Purchase of securities on an exchange or from another person at price $ 17.37 per share. | 11 Dec 2025 | 3,200,000 | 27,307,632 | - | 17.4 | 55,593,600 | Common Stock, $0.01 par value |
| Kenvue | Jeffrey C. Smith | Director | Purchase of securities on an exchange or from another person at price $ 17.43 per share. | 11 Dec 2025 | 3,177,694 | 24,107,632 | - | 17.4 | 55,392,926 | Common Stock, $0.01 par value |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Purchase of securities on an exchange or from another person at price $ 17.69 per share. | 03 Dec 2025 | 500 | 34,109 (0%) | 0% | 17.7 | 8,845 | Common Stock |
| Kenvue | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 1,451 | 13,641 | - | - | Deferred Share Units | |
| Kenvue | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 1,204 | 12,045 | - | - | Deferred Share Units | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 415 | 7,302 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 369 | 7,671 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 3,009 | 13,126 | - | - | Restricted Stock Unit | |
| Kenvue | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 1,061 | 10,734 | - | - | Deferred Share Units | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 289 | 6,886 | - | - | Common Share Equivalent | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Kenvue | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 7,659 | 9,656 | - | - | Deferred Share Units | |
| Kenvue | Jeffrey C. Smith | Director | Other type of transaction at price $ 0.00 per share. | 16 May 2025 | 1,124,062 | 20,929,938 | - | 0 | Common Stock, $0.01 par value | |
| C & F Fin Corp | Jeffery O. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 425 | 2,670 (0%) | 0% | 0 | Common Stock | |
| Kenvue | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 307 | 1,997 | - | - | Deferred Share Units | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 416 | 6,596 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 257 | 6,180 | - | - | Common Share Equivalent | |
| Kenvue | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 1,690 | 1,690 | - | - | Deferred Share Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 519 | 0 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 519 | 87,959 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 4.91 per share. | 03 Mar 2025 | 154 | 87,805 (0%) | 0% | 4.9 | 756 | Common Stock |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Purchase of securities on an exchange or from another person at price $ 18.96 per share. | 28 Jan 2025 | 650 | 33,609 (0%) | 0% | 19.0 | 12,324 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 29,168 | 97,727 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 16,219 | 32,438 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 10,449 | 20,894 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 20 Jan 2025 | 10,287 | 87,440 (0%) | 0% | 4.8 | 49,275 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 79,000 | 79,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 53,000 | 53,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 40,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 11,110 | 8,890 (0%) | 0% | 14.9 | 165,807 | Common Stock |
| Midland States Bancorp Inc | Smith C. Jeffrey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 315 | 5,923 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 183 | 5,607 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 343 | 5,424 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 214 | 5,080 | - | - | Common Share Equivalent | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 9 | 18 | - | - | Dividend Equivalent Rights (RSUs) | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 7 | 27 | - | - | Dividend Equivalent Rights (DSUs) | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2024 | 48,657 | 48,657 | - | - | Restricted Stock Units | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 164 | 2,203 | - | - | Deferred Share Units | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 2,326 | 4,866 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 165 | 2,539 | - | - | Common Share Equivalent | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 9 | 9 | - | - | Dividend Equivalent Rights (RSUs) | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 7 | 20 | - | - | Dividend Equivalent Rights (DSUs) | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 163 | 68,609 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 163 | 0 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 11.80 per share. | 07 Jun 2024 | 50 | 68,559 (0%) | 0% | 11.8 | 590 | Common Stock |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 2,630 | 2,630 | - | - | Restricted Share Units | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 443 | 2,039 | - | - | Deferred Share Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 08 May 2024 | 833 | 68,446 (0%) | 0% | 12 | 9,996 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 31,343 | 31,343 | - | - | Restricted Stock Units | |
| C & F Fin Corp | Jeffery O. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 600 | 2,245 (0%) | 0% | 0 | Common Stock | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 239 | 2,374 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 148 | 2,135 | - | - | Common Share Equivalent | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 451 | 1,596 | - | - | Deferred Share Units | |
| Ritchie Bros Auctioneers Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 7 | 13 | - | - | Dividend Equivalent Rights | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 12.42 per share. | 29 Feb 2024 | 1,006 | 67,248 (0%) | 0% | 12.4 | 12,495 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 519 | 519 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 519 | 67,767 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 29 Feb 2024 | 154 | 67,613 (0%) | 0% | 10.3 | 1,589 | Common Stock |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 75,015 | 2,015,269 (3%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 75,015 | 149,985 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Smith Jeff | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 20 Jan 2024 | 28,000 | 1,987,269 (3%) | 0% | 0.4 | 10,360 | Common Stock |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 152 | 1,906 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Smith Jeffrey C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 80 | 1,986 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2023 | 150 | 1,644 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2023 | 108 | 1,753 | - | - | Common Share Equivalent | |
| Cambridge Bancorp | Jeffrey F. Smith | EVP/Head of Wealth Mgmt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 8,811 | 8,811 (0%) | 0% | 0 | Common Stock | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 4,872 | 4,872 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 4,872 | 1,935,079 (3%) | 0% | - | Common Stock | |
| C & F Fin Corp | Jeffery O. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 500 | 1,645 (0%) | 0% | 0 | Common Stock | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 105 | 1,232 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 103 | 1,127 | - | - | Common Share Equivalent | |
| Midland States Bancorp Inc | Jeffrey C. Smith | Director | Purchase of securities on an exchange or from another person at price $ 23.13 per share. | 13 Mar 2023 | 330 | 32,106 (0%) | 0% | 23.1 | 7,633 | Common Stock |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 937,564 | 312,521 (0%) | 2% | 82.5 | 77,367,781 | Common Stock, par value $0.01 per share |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 429,630 | 0 (0%) | 1% | 82.5 | 35,453,068 | Common Stock, par value $0.01 per share |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 309,080 | 103,027 (0%) | 0% | 82.5 | 25,505,282 | Common Stock, par value $0.01 per share |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 175,544 | 58,514 (0%) | 0% | 82.5 | 14,485,891 | Common Stock, par value $0.01 per share |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 132,253 | 44,085 (0%) | 0% | 82.5 | 10,913,518 | Common Stock, par value $0.01 per share |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 99,259 | 33,086 (0%) | 0% | 82.5 | 8,190,853 | Common Stock, par value $0.01 per share |
| Papa Johns International | Jeffrey C. Smith | See Footnote 1 | Sale or transfer of securities back to the company at price $ 82.52 per share. | 01 Mar 2023 | 93,598 | 31,199 (0%) | 0% | 82.5 | 7,723,707 | Common Stock, par value $0.01 per share |